This week, PharmaCompass continued its analysis of the top 10 fastest-growing drugs of 2016 by sales to evaluate the drugs that registered large sales growth. Please note that these are not the top-selling drugs, but are the top 10 drugs that registered the maximum growth in global sales over 2015. Interestingly, things didn’t appear that[…]
Chemical entities SHINE in the top 10 fastest-growing drugs of 2016
Anti-Retroviral / Anti-HIV, Blood Product, Chemotherapeutic / Anti-Neoplastic, Drug Research & Development API, FDA Approved 2014, FDA Approved 2015 Tags: GileadPfizer May 26, 2017
FDA Announces Approval of Gileads Once-A-Day Pill Sofosbuvir
Antiviral, Drug Research & Development API Tags: GileadHepatitis CSofosbuvir Dec 10, 2013
On December 6th, 2013 the FDA announced the approval of Gilead’s once-a-day pill Sofosbuvir, marketed as Sovaldi. The approval comes shortly after an FDA advisory committee awarded Gilead breakthrough therapy status for the once-a-day pill Sofosbuvir at the end of October 2013 (see previous Sofosbuvir article). The FDA committee also unanimously recommended the approval of[…]
FDA Grants Sofosbuvir Breakthrough Therapy Designation
Anti-Retroviral / Anti-HIV, Antiviral, FDA Breakthrough Therapy Status Tags: GileadHepatitis CribavirinSofosbuvir Nov 01, 2013
The end of October 2013 saw a nod from the FDA given to Gilead’s New Drug Application for Sofosbuvir. As a greatly needed treatment for hepatitis C Sofosbuvir has proven to be effectual and tolerable in a number of studies. Sofosbuvir is marketed by Gilead Science, Inc. and is clearly set up for success in[…]
Exercise is Possible for Patients Suffering from PAH with Ambrisentan
Patent Expiration 2014, Respiratory Tract Agent Tags: GileadPAHpulmonary arterial hypertension Aug 01, 2012
Patients suffering from debilitating pulmonary arterial hypertension, or PAH, find extensive relief when treated with ambrisentan. Also known as the brand name Letairis, marketed by Gilead, ambrisentan is effectual at preventing the thickening of the blood vessels, particularly those in the heart and lungs. Ambrisentan, CAS number 177036-94-1, treats the high blood pressure in the[…]
Adefovir Dipivoxil Effective Treatment for Patients with Chronic Hepatitis B
Anti-Retroviral / Anti-HIV, Drug Research & Development API Tags: chronic hepatitis BGilead Apr 30, 2012
Adefovir dipivoxil, CAS number 142340-99-6, is a nucleotide analog reverse transcriptase inhibitor, or “ntRTI”. Previously called bis-POM PMEA, adefovir dipivoxil is used is the treatment of chronic hepatitis B. Also produced under the trade names Hepsera and Preveon, adefovir dipivoxil is approved by the FDA for treatment in patients with active cases of chronic hepatitis[…]
